Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

3.1K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
3.1K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

3.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".

International journal of hematology·2026
Same author

Preoperative low-attenuation area on computed tomography is associated with recurrence after curative resection for non-small-cell lung cancer.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same author

Methoxy-Functionalized Conjugated Self-Assembled Monolayers as a Hole-Selective Contact for Inverted Perovskite Solar Cells.

ACS applied materials & interfaces·2026
Same author

Mid-Term Outcomes of Titanium Plate Reconstruction for Lung Cancer Requiring Chest Wall Resection.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same author

Single-stage open window thoracostomy with simultaneous muscle flap transposition and early negative pressure wound therapy for chronic empyema: a propensity score- and machine learning-based study.

Journal of cardiothoracic surgery·2026
Same author

Clinical significance of TP53 mutations in patients with acute myeloid leukemia: the HM-SCREEN-JAPAN 01/02 study.

International journal of hematology·2026

Related Experiment Video

Updated: May 5, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

959

Ever-advancing chronic myeloid leukemia treatment.

Shinya Kimura1, Toshihiko Ando, Kensuke Kojima

  • 1Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan, shkimu@cc.saga-u.ac.jp.

International Journal of Clinical Oncology
|November 22, 2013
PubMed
Summary

Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment. Newer TKIs target resistance mutations, offering hope for overcoming CML with oral medications.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.2K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

2.7K

Related Experiment Videos

Last Updated: May 5, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

959
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.2K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

2.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Imatinib mesylate, a tyrosine kinase inhibitor (TKI), transformed chronic myeloid leukemia (CML) treatment.
  • Resistance and intolerance to imatinib are significant challenges, especially in advanced CML.
  • ABL kinase domain mutations are the primary cause of imatinib resistance.

Purpose of the Study:

  • To review the development of ABL TKIs for CML treatment.
  • To highlight the efficacy of second and third-generation TKIs against resistant CML.
  • To discuss the potential for CML eradication with oral therapies.

Main Methods:

  • Review of scientific literature on ABL TKIs and CML.
  • Analysis of clinical data on imatinib, second-generation TKIs (dasatinib, nilotinib, bosutinib, bafetinib), and third-generation TKIs (ponatinib).
  • Examination of mechanisms of TKI resistance, including the T315I mutation.

Main Results:

  • Second-generation TKIs show improved efficacy over imatinib and target some resistance mutations.
  • The T315I mutation remains resistant to second-generation TKIs.
  • Ponatinib effectively targets the T315I mutation and other resistant forms of BCR-ABL.
  • Cessation of TKI therapy is possible for some CML patients achieving deep molecular response.

Conclusions:

  • ABL TKIs have significantly advanced CML therapy, with newer generations overcoming resistance.
  • Targeting specific mutations like T315I with agents like ponatinib is crucial for difficult-to-treat CML.
  • CML may become the first cancer cured solely by oral medications, signifying a paradigm shift in cancer treatment.